Recommended Treatments for Common Acute Medical Conditions
INFECTIONS
Dengue
Dengue requires supportive care only—no specific antiviral therapy exists, and management focuses on aggressive fluid replacement to prevent shock. 1 Treatment is entirely symptomatic with close monitoring for warning signs of severe dengue (plasma leakage, hemorrhage, organ impairment). Fluid resuscitation is the cornerstone of management 2. Avoid NSAIDs due to bleeding risk; use acetaminophen for fever control. Monitor platelet counts, hematocrit, and vital signs closely. Hospitalization is indicated for warning signs or severe dengue 3.
Common pitfall: Attempting antibiotic therapy—dengue is viral and antibiotics provide no benefit unless secondary bacterial infection is documented.
Malaria
Immediate empiric antimalarial treatment must be initiated in any febrile patient returning from malaria-endemic regions while awaiting diagnostic confirmation 4, 5. Treatment choice depends on species identification and severity:
- Severe malaria: IV artesunate (preferred) or IV quinine
- Uncomplicated P. falciparum: Artemisinin-based combination therapy (ACT)
- Diagnostic confirmation via thick/thin blood smears or rapid diagnostic tests is essential but should not delay treatment in critically ill patients 4
Critical point: Malaria is the most common life-threatening tropical infection and requires immediate treatment—delays increase mortality 4, 5.
Typhoid (Enteric Fever)
Antimicrobial choice must be guided by local resistance patterns, with azithromycin or ceftriaxone as first-line agents in most settings 6, 3. Treatment options include:
- Fluoroquinolone-susceptible strains: Ciprofloxacin (though resistance is widespread)
- Fluoroquinolone-resistant strains: Azithromycin (preferred oral) or ceftriaxone (IV)
- Extensively drug-resistant (XDR) typhoid: Azithromycin plus meropenem 6
- Duration: 7-14 days depending on severity and agent used
Blood cultures should be obtained before antibiotics but treatment should not be delayed in severely ill patients 3.
Viral Fever (Non-specific)
Supportive care only—avoid empiric antibiotics unless bacterial infection is documented or highly suspected 7, 8. Management includes:
- Antipyretics (acetaminophen preferred)
- Adequate hydration
- Rest and symptomatic relief
- Monitor for development of specific syndromes requiring targeted therapy
Key principle: Most viral fevers are self-limited and antibiotic use drives resistance without benefit 7.
Acute Gastroenteritis
Oral or IV rehydration is the primary treatment; antibiotics are indicated only for specific pathogens or severe disease 9. Approach:
- Mild-moderate dehydration: Oral rehydration solution
- Severe dehydration: IV isotonic crystalloids
- Antibiotics indicated for: Shigella (dysentery), Campylobacter in severe cases, suspected cholera
- Avoid antibiotics for: Viral gastroenteritis, most E. coli infections, Salmonella (prolongs carrier state)
Pneumonia (Community-Acquired)
Empiric antibiotic therapy must be initiated within 4 hours of diagnosis, with regimen based on severity assessment 7, 9.
Non-severe pneumonia (outpatient/low-risk):
- First-line: Amoxicillin or doxycycline
- Alternative: Macrolide (azithromycin/clarithromycin) for penicillin allergy 7
- Duration: 7 days for uncomplicated cases 7
Severe pneumonia (hospitalized):
- IV combination therapy: Beta-lactam (ceftriaxone/cefotaxime or co-amoxiclav) PLUS macrolide (clarithromycin) 7
- Alternative: Respiratory fluoroquinolone (levofloxacin/moxifloxacin) plus beta-lactam 7
- Duration: 10 days; extend to 14-21 days for S. aureus or gram-negative pathogens 7
- Switch to oral therapy when clinically improved and afebrile for 24 hours 7
Critical action: Obtain blood cultures and sputum cultures before antibiotics, but do not delay treatment 10.
UTI and Pyelonephritis
Uncomplicated pyelonephritis can be treated with shorter courses (7-10 days) following effective source control 11.
Uncomplicated UTI (cystitis):
- Nitrofurantoin, trimethoprim-sulfamethoxazole, or fosfomycin (3-5 days)
Pyelonephritis:
- Outpatient: Fluoroquinolone (ciprofloxacin/levofloxacin) or ceftriaxone
- Inpatient: IV fluoroquinolone or 3rd generation cephalosporin
- Duration: 7-10 days for uncomplicated cases 11
- Obtain urine culture before treatment; adjust based on susceptibilities
Cellulitis
Empiric therapy should cover Streptococcus and Staphylococcus aureus, with MRSA coverage added based on local prevalence and severity 9.
Non-purulent cellulitis:
- Oral: Cephalexin, dicloxacillin, or amoxicillin-clavulanate
- IV (severe): Cefazolin or ceftriaxone
Purulent/MRSA suspected:
- Oral: Trimethoprim-sulfamethoxazole, doxycycline, or clindamycin
- IV (severe): Vancomycin or linezolid
Duration: 5-10 days depending on response.
Leptospirosis
Doxycycline or penicillin should be initiated promptly in suspected cases, particularly in endemic areas or after freshwater exposure 4.
- Mild-moderate: Doxycycline 100 mg PO twice daily for 7 days
- Severe (Weil's disease): IV penicillin G or ceftriaxone
- Early treatment (within 5 days of symptom onset) reduces severity and duration 4
RESPIRATORY CONDITIONS
Asthma Exacerbation
Immediate treatment requires inhaled beta-agonists, systemic corticosteroids, and oxygen to maintain SpO2 >90%.
Acute management:
- Inhaled SABA: Albuterol via nebulizer or MDI with spacer (2.5-5 mg every 20 minutes × 3 doses)
- Systemic corticosteroids: Prednisone 40-60 mg PO or methylprednisolone 60-125 mg IV
- Oxygen: Target SpO2 93-95%
- Ipratropium bromide: Add to SABA for severe exacerbations
- Magnesium sulfate: 2 g IV over 20 minutes for severe/life-threatening cases
Disposition: Discharge if FEV1 or peak flow >70% predicted after treatment; otherwise admit.
COPD Exacerbation
Bronchodilators, systemic corticosteroids, and antibiotics (if purulent sputum or severe) form the treatment triad 12.
Management:
- Bronchodilators: SABA + SAMA (albuterol + ipratropium) via nebulizer
- Corticosteroids: Prednisone 40 mg PO daily for 5 days or methylprednisolone 125 mg IV
- Antibiotics (if purulent sputum or severe): Amoxicillin-clavulanate, doxycycline, or macrolide targeting S. pneumoniae, H. influenzae, M. catarrhalis 12
- Oxygen: Titrate to SpO2 88-92% (avoid hyperoxia)
- Ventilatory support: NIV (BiPAP) for respiratory acidosis or severe dyspnea
Acute Bronchitis
Antibiotics are NOT routinely indicated for acute bronchitis in previously healthy adults—this is predominantly viral 7, 8, 7.
Management:
- Symptomatic treatment: antitussives, bronchodilators if wheezing
- Consider antibiotics only if: Worsening symptoms, recrudescent fever, or high-risk patients (elderly, immunocompromised) with lower respiratory features 7, 8
- If antibiotics needed: Amoxicillin-clavulanate, doxycycline, or macrolide 7
Major pitfall: Overuse of antibiotics for viral bronchitis drives resistance without clinical benefit 7.
CARDIAC AND METABOLIC
Hypertensive Urgency
Gradual blood pressure reduction over 24-48 hours with oral agents—avoid rapid drops that risk end-organ hypoperfusion.
Management:
- Oral agents: Labetalol, amlodipine, clonidine, or captopril
- Target: Reduce BP by 25% over first 24 hours, then to 160/100 over next 24-48 hours
- Avoid: IV agents (reserved for hypertensive emergency with end-organ damage)
- Investigate for secondary causes and medication non-adherence
Heart Failure (Acute Decompensation)
Diuretics, vasodilators, and oxygen form the immediate treatment approach, with careful fluid balance monitoring.
Acute management:
- IV loop diuretic: Furosemide 40-80 mg IV (double home dose if on chronic diuretics)
- Oxygen: Target SpO2 >90%
- Vasodilators (if SBP >90): Nitroglycerin IV or sublingual
- Positioning: Upright to reduce preload
- Monitor: Daily weights, strict I/O, electrolytes (especially potassium)
- Avoid: Excessive fluid administration
Medically Managed ACS (Angina/NSTEMI)
Dual antiplatelet therapy, anticoagulation, beta-blockers, and statins must be initiated immediately alongside risk stratification.
Immediate treatment:
- Antiplatelet: Aspirin 162-325 mg chewed + P2Y12 inhibitor (clopidogrel 300-600 mg or ticagrelor 180 mg)
- Anticoagulation: Heparin (UFH or LMWH) or fondaparinux
- Beta-blocker: Metoprolol or carvedilol (if no contraindications)
- Statin: High-intensity (atorvastatin 80 mg)
- Nitrates: Sublingual or IV for ongoing chest pain
- ACE inhibitor: If LV dysfunction or anterior MI
Risk stratification: TIMI or GRACE score guides timing of angiography.
Special consideration: Dengue can present with ACS-like features; maintain high suspicion in endemic areas 2.
Diabetic Ketoacidosis
Aggressive IV fluid resuscitation, insulin infusion, and electrolyte replacement with close monitoring are essential.
Management protocol:
- Fluids: 0.9% saline 1-1.5 L in first hour, then 250-500 mL/hr (switch to 0.45% saline if hypernatremic)
- Insulin: Regular insulin 0.1 units/kg/hr IV infusion (after initial bolus if glucose >250 mg/dL)
- Potassium: Replace if <5.3 mEq/L (hold insulin if <3.3 mEq/L)
- Glucose: When <200 mg/dL, add dextrose to fluids and continue insulin until anion gap closes
- Monitor: Hourly glucose, q2-4h electrolytes and VBG until resolved
Resolution criteria: Glucose <200 mg/dL, anion gap <12, pH >7.3, bicarbonate >18 mEq/L.
Hypoglycemia
Immediate glucose administration (IV dextrose or IM glucagon) followed by investigation of underlying cause.
Treatment:
- Conscious patient: 15-20 g oral glucose (juice, glucose tablets)
- Altered/unconscious: Dextrose 50% 25-50 mL IV (or D10 150-250 mL) OR glucagon 1 mg IM/SC
- Recheck glucose in 15 minutes; repeat if <70 mg/dL
- Continuous dextrose infusion if recurrent or sulfonylurea-induced
- Octreotide for refractory sulfonylurea-induced hypoglycemia
Investigate: Medication review, missed meals, renal failure, sepsis, adrenal insufficiency.
Hyponatremia
Treatment intensity depends on severity of symptoms and chronicity—rapid correction risks osmotic demyelination syndrome.
Symptomatic/severe (Na <120 or seizures):
- 3% hypertonic saline: 100 mL IV bolus over 10 minutes, repeat up to 3 times
- Target: Increase Na by 4-6 mEq/L in first hours (stop when symptoms resolve)
- Maximum correction: 8 mEq/L in 24 hours, 18 mEq/L in 48 hours
Asymptomatic/chronic:
- Fluid restriction (800-1000 mL/day) for SIADH
- Treat underlying cause: Heart failure (diuretics), hypothyroidism (levothyroxine)
- Slow correction: 0.5 mEq/L per hour maximum
Critical pitfall: Overcorrection causes irreversible neurologic damage.
GASTROINTESTINAL
Acute Pancreatitis
Aggressive IV fluid resuscitation, pain control, and nutritional support with avoidance of prophylactic antibiotics 11.
Management:
- Fluids: Lactated Ringer's 250-500 mL/hr (goal: UOP >0.5 mL/kg/hr, decrease BUN)
- Analgesia: Opioids as needed (morphine, hydromorphone)
- Nutrition: Early enteral feeding (within 24-48 hours) preferred over NPO
- Antibiotics: NOT indicated prophylactically 11; use only for documented infected necrosis (after 7-10 days with FNA confirmation) 11
- Monitor: Lipase, calcium, glucose, LFTs; imaging if diagnosis uncertain or complications suspected
Source control: Infected pancreatic necrosis requires delayed intervention (weeks) after demarcation 11.
Gastritis
Proton pump inhibitors provide symptom relief and mucosal healing; identify and treat underlying causes.
Treatment:
- PPI: Omeprazole 20-40 mg daily or pantoprazole 40 mg daily
- H. pylori testing: If positive, triple therapy (PPI + clarithromycin + amoxicillin) for 14 days
- Avoid: NSAIDs, alcohol, smoking
- Consider: H2-blocker (famotidine) as alternative
GI Bleed
Resuscitation, risk stratification, PPI therapy, and endoscopy within 24 hours for upper GI bleeds.
Immediate management:
- Resuscitation: 2 large-bore IVs, crystalloid bolus, type and cross
- Transfusion threshold: Hemoglobin <7 g/dL (or <8 g/dL if CAD)
- PPI: Pantoprazole 80 mg IV bolus then 8 mg/hr infusion (for upper GI bleed)
- Antibiotics: Ceftriaxone 1 g IV daily if cirrhosis (prevents bacterial infections and rebleeding)
- Endoscopy: Within 24 hours for upper GI bleed; colonoscopy after prep for lower GI bleed
- Octreotide: 50 mcg bolus then 50 mcg/hr infusion if variceal bleeding suspected
Risk stratification: Glasgow-Blatchford score guides disposition.
Hepatitis/Jaundice
Identify etiology through history, labs (hepatitis serologies, autoimmune markers), and imaging; treatment is cause-specific.
Initial workup:
- Labs: LFTs, hepatitis A/B/C serologies, INR, albumin, bilirubin (direct/indirect)
- Imaging: Right upper quadrant ultrasound to assess biliary obstruction
- Additional: Autoimmune markers (ANA, ASMA), ceruloplasmin, iron studies as indicated
Management:
- Viral hepatitis: Supportive care; consider antivirals for HBV/HCV (specialist consultation)
- Autoimmune hepatitis: Corticosteroids (prednisone)
- Drug-induced: Discontinue offending agent (acetaminophen toxicity: N-acetylcysteine)
- Biliary obstruction: ERCP for choledocholithiasis
- Avoid: Hepatotoxic medications, alcohol
Monitor: Coagulopathy (INR), encephalopathy, ascites—signs of acute liver failure requiring ICU/transplant evaluation.
KEY PRINCIPLES ACROSS CONDITIONS
Sepsis recognition: Any infection with organ dysfunction requires immediate treatment per Surviving Sepsis guidelines 11:
- Fluid resuscitation: 30 mL/kg crystalloid within 3 hours
- Antibiotics: Within 1 hour of recognition, broad-spectrum empiric coverage
- Source control: Within 12 hours if indicated 11
- Vasopressors: Norepinephrine if MAP <65 mmHg despite fluids 13
Antibiotic stewardship: Daily reassessment for de-escalation based on cultures and clinical response 11. Duration 7-10 days adequate for most infections 11.